25 results about "Wasting" patented technology

This disclosure provides a secretion centric therapy to overcome muscle wasting. Provided are mesenchymal stem cell secretion-based therapies to overcome muscle wasting due to: old age; as a consequence of immobilization (e.g., mobility restricted or paralytics administered); due to use of ventilators (e.g., in an ICU or long-term immobilization); in microgravity during long space flights; or, resulting from drug side effects (e.g., the use of weight loss drugs, chemotherapies, etc.). This disclosure further provides methods and compositions for modulating, including regulating or altering, the structure and function of diaphragm muscle cells and / or diaphragm muscle fibers in particular, and skeletal muscle in general. In certain embodiments extracellular vesicles are applied to patients affected by muscle wasting.

The invention discloses an anti-muscle attenuation composition and application thereof, and the composition provided by the invention comprises an anti-muscle attenuation peptide, WPC, MLCT and CaHMB; the muscle attenuation resisting peptide is zymolyte obtained after milk protein is subjected to protease enzymolysis, the zymolyte comprises polypeptide with the absolute net charge density ridge-shaped region distribution of a peptide chain formed by a head peptide fragment, a middle peptide fragment and a tail peptide fragment, the head peptide fragment is j1, the middle peptide fragment is j2, and the tail peptide fragment is j3; the charge density of the j1 and the charge density of the j3 are both larger than the charge density of the j2, or the charge density of the j1 and the charge density of the j3 are both smaller than the charge density of the j2. Through mutual cooperation of the muscle attenuation resisting peptide, the WPC, the MLCT and the CaHMB, the effect of obviously improving the muscle attenuation resisting effect is achieved.

Provided herein are codon-optimized Smad7 polynucleotides and vectors comprising codon-optimized Smad7 polynucleotides for use in increasing or prolonging Smad7 expression in a subject.

This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain embodiments, the ActRII-binding proteins inhibit, or antagonize ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated with muscle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.

Disclosed herein are novel beta-alanine compositions for increasing athletic performance, improving cognitive function, and attenuating the aging process. Compositions described herein can be administered to subjects, such as elderly subject, in functional or medical foods, along with other formulations to aid in healthy aging including reduced muscle wasting, improved mobility, improved cognitive performance, and the like. The compositions described herein comprise improved bioavailability and reduced paresthesia effects compared to free beta-alanine. Also described herein are methods of making the novel beta-alanine compositions disclosed herein.

This disclosure provides a secretion centric therapy to overcome muscle wasting. Provided are mesenchymal stem cell secretion-based therapies to overcome muscle wasting due to: old age; as a consequence of immobilization (e.g., mobility restricted or paralytics administered); due to use of ventilators (e.g., in an ICU or long-term immobilization); in microgravity during long space flights; or, resulting from drug side effects (e.g., the use of weight loss drugs, chemotherapies, etc.). Uris disclosure further provides methods and compositions for modulating, including regulating or altering, the structure and function of diaphragm muscle cells and / or diaphragm muscle fibers in particular, and skeletal muscle in general. In certain embodiments extracellular vesicles are applied to patients affected by muscle wasting.

The invention pertains to a nutritional composition comprising taurine, carnitine and a mixture of low- molecular-weight polyphenols derived from lychee fruit and green tea leaves. Further, the invention pertains to a nutritional composition comprising taurine, carnitine and a mixture of low-molecular-weight polyphenols derived from lychee fruit and green tea leaves for use as a medicament, more particularly for therapeutic use in treating and / or preventing muscle wasting.

Described herein are treatment regimens, therapies, pharmaceutical formulations and methods of using quercetin to prevent, treat, and / or protect from muscle wasting including 1) sarcopenia associated with aging; and 2) cachexia associated with chronic diseases and their treatments including but not limited to cancer, cardiovascular disease, chronic obstructive pulmonary disease (COPD), HIV, and kidney disease.

The invention discloses lactoprotein hydrolysate with peptide chain absolute net charge density ridge-shaped region distribution and application in muscle attenuation resistance activity, the lactoprotein hydrolysate comprises polypeptide with peptide chain absolute net charge density ridge-shaped region distribution formed by head, middle and tail peptide fragments, the head peptide fragment is j1, the middle peptide fragment is j2, the tail peptide fragment is j3, the middle peptide fragment is j1, and the tail peptide fragment is j2. The charge density of the j1 ranges from-0.0241 e <-1 > / 3 to-0.1224 e <-1 > / 3, the charge density of the j2 ranges from-0.0083 e <-1 > / 3 to-0.1238 e <-1 > / 3, the charge density of the j3 ranges from-0.0472 e <-1 > / 3 to-0.1752 e <-1 > / 3, the charge density of the j1 and the charge density of the j3 are both larger than the charge density of the j2, or the charge density of the j1 and the charge density of the j3 are both smaller than the charge density of the j2. The lactoprotein zymolyte provided by the invention is suitable for preparing products with muscle quality and functional decline characteristics such as prevention or delay of muscle attenuation and the like.

Provided herein are method to prevent or treat cancer cachexia by administering a combination of a JAK inhibitor and a TLR4 inhibitor. Cancer cachexia is a severe condition characterized by weight loss and muscle wasting. By administering an effective amount of a JAK inhibitor and a TLR4 inhibitor to a subject, the subject has improved appetite, weight gain, and enhanced overall survival. The method can include additional therapeutic agents, such as chemotherapy, immunotherapy or surgery.

There is provided herein a method of treatment comprising: (i) a first treatment cycle comprising administration of a therapeutically effective amount of a therapeutic agent, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the therapeutic agent directly or indirectly induces muscle wasting; and (ii) a second treatment cycle following the discontinuation of the first treatment cycle, wherein the second treatment cycle comprises administration of a therapeutically effective amount of a β2-adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof, to the subject, wherein the first and second treatment cycles are within the same therapeutic intervention.

This disclosure provides a secretion centric therapy to overcome muscle wasting. Provided are mesenchymal stem cell secretion-based therapies to overcome muscle wasting due to: old age; as a consequence of immobilization (e.g., mobility restricted or paralytics administered); due to use of ventilators (e.g., in an ICU or long-term immobilization); in microgravity during long space flights; or, resulting from drug side effects (e.g., the use of weight loss drugs, chemotherapies, etc.). This disclosure further provides methods and compositions for modulating, including regulating or altering, the structure and function of diaphragm muscle cells and / or diaphragm muscle fibers in particular, and skeletal muscle in general. In certain embodiments extracellular vesicles are applied to patients affected by muscle wasting.

The present invention relates to compositions comprising branched-chain amino acids (BCAA) and the amino acid L-Alanine and their use in the prevention and / or treatment of muscle wasting associated to pathological or age-related conditions.

This disclosure provides a secretion centric therapy to overcome muscle wasting. Provided are mesenchymal stem cell secretion-based therapies to overcome muscle wasting due to: old age; as a consequence of immobilization (e.g., mobility restricted or paralytics administered); due to use of ventilators (e.g., in an ICU or long-term immobilization); in microgravity during long space flights; or, resulting from drug side effects (e.g., the use of weight loss drugs, chemotherapies, etc.). This disclosure further provides methods and compositions for modulating, including regulating or altering, the structure and function of diaphragm muscle cells and / or diaphragm muscle fibers in particular, and skeletal muscle in general. In certain embodiments extracellular vesicles are applied to patients affected by muscle wasting.

The present invention relates to a compound of the general formula I and the pharmaceutically acceptable salts thereof; where the variables are as defined in the claims and the description. The invention also relates to the compounds of formula I for use in the treatment or prophylaxis of muscle wasting conditions, of skeletal or cardial muscle atrophy, of conditions, in particular of myopathies, which are associated with an increased Muscle RING Finger 1 (MuRF1) expression and of other conditions; to the compounds of formula I for use as a medicament; to a pharmaceutical composition comprising at least one compound of formula I and to a method for treating said conditions.

The invention pertains to a nutritional composition comprising xanthohumol, fucoxanthin and c- phycocyanin. Further, the invention pertains to a nutritional composition comprising xanthohumol, fucoxanthin and c-phycocyanin for use as a medicament, more particularly for therapeutic use in treating and / or preventing muscle wasting.

Activin receptor type II (ActRII) - binding proteins, and compositions and methods for making ActRII-binding proteins are provided.SOLUTION: To provide isolated ActRII-binding proteins having specific sequences and binding to activin receptor type IIB (ActRIIB) or ActRIIB and activin receptor type IIA (ActRIIA). In certain aspects, the ActRII-binding protein inhibits or antagonizes ActRII activity. In addition, the disclosure provides compositions and methods of diagnosing and treating diseases and conditions associated with muscle wasting; fibrotic conditions; inflammatory, cardiovascular, pulmonary, musculoskeletal, neurological, ocular, skeletal, autoimmune, or metabolic diseases or conditions; wound healing; and cancer, and other ActRII-mediated diseases and conditions.SELECTED DRAWING: Figure 6

This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain embodiments, the ActRII-binding proteins inhibit, or antagonize ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated with muscle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.

Use of a ketone body and a ketone body ester for preserving glycogen and / or protein, thereby reducing muscle breakdown and improving endurance during exercise and promoting muscle recovery following exercise. Also for retarding muscle wasting in aging and disease. (R)-3-hydroxybutyl (R)-3-hydroxybutyrate for use in reducing muscle glycogen and protein breakdown during exercise or decreasing muscle wasting in aging and disease. Certain esters of hydroxybutyrate monomers, particularly a monoester of D-β-hydroxybutyrate with R-1,3-butanediol or with glycerol to reduce muscle breakdown and aid muscle recovery after exercise or retard muscle wasting. Compositions containing the ketone bodies or ketone body esters are also described.

Products, methods, and uses for treating, ameliorating, delaying the progression ui, and / or preventing a disease or disorder associated with expression of an aberrant lamin A (LMNA) gene or progerin gene are provided. Such disease or disorder includes, but is not limited to, a laminopathy, progeroid syndrome, progeria, or aging disorder resulting from the aberrant expression of LMNA or progerin. In some instances, the progeria is Hutchinson- Gilford progeria syndrome (HOPS). In some instances, the disease or disorder associated with the expression of progerin is premature aging or natural aging including, but not limited to, atherosclerosis, alopecia, osteoporosis, cardiovascular disease, skin abnormalities, fat storage, stroke, myocardial infarction, stroke, heart failure, muscle wasting, muscle weakness, myotonia, skeletal muscle problems, abnormalities of the retina, hip weakness, abdominal muscle weakness, joint and spinal abnormalities, lower leg weakness, shoulder weakness, hearing loss, and / or tissue inflammation. More particularly, disclosed herein are RNA interference-based products, methods, and uses for inhibiting or downregulating the expression of progerin. Even more particularly, the disclosure provides microRNA (miRNA) for inhibiting or downregulating the expression of progerin and methods of using said miRNA to inhibit or downregulate progerin expression in cells and / or in cells of a subject having a condition resulting from the expression of progerin including, but not limited to, HGPS or progeria, an HGPS-like condition affecting LMNA mutations that affect exon 11 splicing, or a condition resulting from the expression of progerin.

The present disclosure relates generally to methods and compositions comprising trigonelline for treating or preventing diseases or conditions associated with muscle decline and / or renal dysfunction. In addition, the invention relates to methods and compositions comprising trigonelline for slowing the progression of glomerular filtration rate (GFR) and / or reducing glomerular vitreous lesion injury and / or increasing lean body mass of the muscle. In addition, methods and compositions comprising trigonelline are disclosed for increasing lean body mass of the muscle and / or increasing muscle fiber size. Also disclosed are methods for increasing the level of at least one nicotinamide adenine dinucleotide and compositions comprising trigonelline. Methods and compositions comprising trigonelline for increasing muscle stem cells and / or reducing muscle stem cell decline are also disclosed.

Disclosed herein are novel beta-alanine compositions for increasing athletic performance, improving cognitive function, and attenuating the aging process. Compositions described herein can be administered to subjects, such as elderly subject, in functional or medical foods, along with other formulations to aid in healthy aging including reduced muscle wasting, improved mobility, improved cognitive performance, and the like. The compositions described herein comprise improved bioavailability and reduced paresthesia effects compared to free beta-alanine. Also described herein are methods of making the novel beta-alanine compositions disclosed herein.

Provided herein are codon-optimized Smad7 polynucleotides and vectors comprising codon-optimized Smad7 polynucleotides for use in increasing or prolonging Smad7 expression in a subject.

Provided herein are method to prevent or treat cancer cachexia by administering a combination of a JAK inhibitor and a TLR4 inhibitor. Cancer cachexia is a severe condition characterized by weight loss and muscle wasting. By administering an effective amount of a JAK inhibitor and a TLR4 inhibitor to a subject, the subject has improved appetite, weight gain, and enhanced overall survival. The method can include additional therapeutic agents, such as chemotherapy, immunotherapy or surgery.

The present disclosure relates to methods, uses, compositions, and kits for improving muscle mass, muscle strength, or muscle function or for reducing fatigue, pain, or obesity in a subject using testosterone or testosterone derivative and growth hormone (GH) or GH derivative. One aspect of this disclosure relates to a combination therapy of testosterone or testosterone derivative and GH or GH derivative for treating various disorders associated with muscle wasting or conditions associated with muscle weakness.